Billionaire Ken Griffin Boosted His Stake in This Dividend King by 146%. Here's Why It's a Dream Stock for Risk-Averse Investors.

1 hour ago 1

Adria Cimino, The Motley Fool

Sun, July 12, 2026 astatine 4:30 PM CDT 5 min read

Investors wage cautious attraction to Ken Griffin's moves for 1 large reason: The laminitis of Citadel has an highly coagulated way grounds of success. Citadel, which oversees $69 billion, successful January was named the astir profitable hedge money ever, winning this accolade for the 4th consecutive year.

Griffin's funds besides carried their occurrence done the archetypal fractional of this year, with affirmative returns crossed strategies, according to a caller CNBC report. The billionaire uses a assortment of techniques, including focuses connected in-depth probe and managing risk, successful bid to present the strongest imaginable returns successful immoderate marketplace environment.

Missed Nvidia successful 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" awesome flashed for a little-known chipmaker called Nvidia. For the archetypal clip successful years, that aforesaid "Total Conviction" awesome is flashing for a institution 1/100th the size of Nvidia. Continue »

With each of this successful mind, let's see 1 of the billionaire's latest moves. He boosted his involvement successful 1 peculiar Dividend King by 146% successful the archetypal quarter. Here's wherefore it's an perfect prime for investors who are uncomfortable with risk.

Two investors look astatine thing connected a laptop.

A sanction you whitethorn cognize good

This peculiar banal is simply a sanction you mightiness cognize well, acknowledgment to assorted user wellness products the institution utilized to merchantability -- from Band-Aid bandages to Tylenol. It spun disconnected that concern arsenic Kenvue a fewer years agone successful bid to absorption connected its 2 halfway businesses of pharmaceuticals and medtech. I'm talking astir Johnson & Johnson (NYSE: JNJ).

In the archetypal quarter, Ken Griffin accrued his presumption successful J&J by 146% and present holds 1,930,976 shares. The stock, astatine 0.08% of the portfolio, isn't a immense presumption -- but its beingness determination since 2017 suggests Griffin recognizes J&J arsenic a cardinal semipermanent winner.

Now, let's speech astir wherefore this banal is specified a large holding for risk-averse investors. First, it's important to see the Kenvue spinoff. Though J&J whitethorn person go a household sanction acknowledgment to its user products, user wellness really wasn't a immense maturation operator for the company. Pharmaceuticals -- known arsenic the innovative medicine concern -- and medtech offered greater maturation potential, truthful J&J wanted to give much resources to these units.

The stake has already proven to beryllium a astute one, arsenic gross has climbed successful caller quarters. The latest 1 is the cleanable example. Innovative medicine income jumped 11%, portion medtech income precocious much than 7%. And wide worldwide income accrued astir 10% to much than $24 billion.